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Abstract: Estrogen receptor alpha (ERα) signaling pathways are frequently disrupted in breast cancer
and contribute to disease progression. ERα signaling is multifaceted and many ERα regulators
have been identified including transcription factors and growth factor pathways. More recently,
microRNAs (miRNAs) are shown to deregulate ERα activity in breast carcinomas, with alterations
in both ERα and miRNA expression correlating to cancer progression. In this study, we show
that a high expression of Argonaute 2 (AGO2), a translation regulatory protein and mediator of
miRNA function, correlates with the luminal B breast cancer subtype. We further demonstrate that
a high expression of AGO2 in ERα+ tumors correlates with a poor clinical outcome. MCF-7 breast
cancer cells overexpressing AGO2 (MCF7-AGO2) altered ERα downstream signaling and selective
ERα variant expression. Enhanced ERα-36, a 36 kDa ERα isoform, protein and gene expression
was observed in vitro. Through quantitative polymerase chain reaction (qPCR), we demonstrate
decreased basal expression of the full-length ERα and progesterone receptor genes, in addition to loss
of estrogen stimulated gene expression in vitro. Despite the loss, MCF-7-AGO2 cells demonstrated
increased estrogen stimulated tumorigenesis in vivo. Together with our clinical findings on AGO2
expression and the luminal B subtype, we suggest that AGO2 is a regulator of altered ERα signaling
in breast tumors.
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1. Introduction
Breast cancer is one of the most common causes of death in U.S. women [1]. Subtypes of breast
cancer, such as luminal A, luminal B, triple negative/basal-like, and HER2 type, are based on molecular
characteristics including hormone receptor (estrogen receptor (ERα), progesterone receptor (PGR) and
HER2/neu (V-Erb-B2 erythroblastic leukemia viral oncogene homolog 2)) status [2]. An estimated 70%
of all newly diagnosed breast cancer patients are classified as ERα+ and hormone responsive, relying
on estrogen stimulation to maintain tumorigenesis [3]. Alterations in estrogen signaling pathways in
ERα+ breast tumors can arise from increased growth factor signaling, such as epidermal growth factor
receptor (EGFR) and AKT/mammalian target of rapamycin (mTOR) pathways, and more recently to
ERα isoform variation [2,4–8]. ERα-36 is a 36 kDa ERα isoform originating from within a conventional
ERα transcript. Expression of ERα-36, which possesses DNA and ligand binding activity but lacks
activation function-1 (AF-1) and -2 (AF-2) transactivation domains [4,8], has been observed in both
ERα-positive and -negative breast tumors and cell lines [4,8,9]. ERα-36, which is localized to the
plasma membrane and induces rapid estrogen signaling through mitogen activated protein kinase
(MAPK) and phosphoinositide 3-kinase (PI3K)/AKT signaling pathways [8,10], is linked to tamoxifen
resistance in breast cancers and is capable of eliciting agonistic tamoxifen induced signaling [8–10].
Recently, altered ERα signaling by microRNAs (miRNAs) has been observed, with some miRNAs
directly repressing ERα and other miRNAs inducing resistance to endocrine therapies [11–13].
Deregulated miRNA processing and miRNA expression in breast tumor subtypes has also been
reported [14–18]. In addition, the miRNA biogenesis associated proteins are associated with breast
cancer progression. For example, Argonaute 2 (AGO2), a key component of the miRNA silencing
complex and mRNA translational regulatory protein, is directly regulated by ERα signaling via the
MAPK pathway [14]. Among breast tumor types, increased AGO2 expression in ERα− breast cancer
cell lines and tumor samples has been observed [14]. A positive correlation between AGO2 expression
levels and the ERα− phenotype in breast cancer cell lines and tumor samples has been previously
reported with AGO2 expression being regulated by EGFR/MAPK signaling [14]. In this study we
further evaluate the expression of AGO2 across breast cancer tumor samples with different degrees
of receptor status (ERα, PGR, and HER2) and tumor molecular subtype. In addition, we show that
a subset of ERα+ breast tumor samples, characterized as luminal B and ERα+/PGR−, demonstrated
high AGO2 levels, similar to those observed in the ERα− tumor types. AGO2 expression correlates
with a poor clinical outcome in ERα+ breast tumor samples.
2. Results
2.1. Enhanced Expression of AGO2 Is Associated with an ERα− and Luminal B Breast Cancer Phenotype
Analysis of next generation deep sequencing of breast cancer invasive carcinoma gene expression
was derived from The Cancer Genome Atlas (TCGA) data portal and viewed in the UCSC Cancer
Genomics Browser [19–22]. AGO2 gene expression strongly correlated with the more aggressive
and invasive basal-like breast cancer phenotypes and was inversely associated with ERα status
(Figure 1A,B). Interestingly, tumor samples with a breast tumor type categorized as luminal B
(Figure 1A) and an ERα+/PGR− receptor status (Figure 1B) demonstrated high AGO2 expression levels
compared to samples with luminal A/ERα+/PGR+ receptor status. Clinically, luminal B tumor types
can be categorized as having altered estrogen signaling pathways and an ERα+/PGR− phenotype [23].
To further determine the clinical significance of AGO2 expression in breast tumors, univariate Cox
analysis was performed on breast tumor data obtained from the Breast Cancer Gene-Expression Miner
V3.0 [24,25]. Increased AGO2 expression was associated with a negative clinical outcome for ERα+ but
not for ERα− tumor types (Table 1). High levels of AGO2 significantly correlated with an increased
hazard ratio and any event of relapse (AE) free survival (Figure 1C). Furthermore, Kaplan–Meier
analysis of AGO2 expression correlated with a poor prognosis for recurrence free survival in ERα+
breast tumors but not in ERα− tumor samples (Figure 1D). These data illustrate an association between
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AGO2 expression in ERα+ tumors, and suggest AGO2 expression has a negative correlation with
survival in ERα+ tumors.
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Figure 1. Argonaute  2  (AGO2) expression correlates with poor prognosis  in estrogen  receptor  alpha 
positive  (ERα+)  breast  cancer  tumor  samples. RNA deep  sequencing  of The  Cancer Genome Atlas 
(TCGA) breast cancer samples were analyzed for AGO2 expression  in correlation with  (A) molecular 
subtype and (B) receptor status based on clinical scoring. Red indicates high gene expression levels 
and green indicates low gene expression. For receptors ERα, PGR, and HER2, orange shows positive 
and  blue  shows  negative  receptor  expression;  (C)  Forest  plot  of  univariate Cox  analysis  of AGO2 
expression in breast tumor samples, correlation of AGO2 expression and clinical outcome; (D) Kaplan–
Meier analysis of AGO2 expression in ERα+ and ERα− tumor samples with correlation with recurrence 
free survival for pooled breast cancer samples obtained from Breast Cancer Gene‐Expression Miner 
v3.0. AE: number of events associated with survival, death or relapse; HR: hazard ratio. 
Figure 1. Argonaute 2 (AGO2) expression correlates with poor prognosis in estrogen receptor alpha
positive (ERα+) breast cancer tumor samples. RNA deep sequencing of The Cancer Genome Atlas
(TCGA) breast cancer samples were analyzed for AGO2 expression in correlation with (A) molecular
subtype and (B) receptor status based on clinical scoring. Red indicates high gene expression levels and
green indicates low gene expression. For receptors ERα, PGR, and HER2, orange shows positive and
blue shows negative receptor expression; (C) Forest plot of univariate Cox analysis of AGO2 expression
in breast tumor samples, correlation of AGO2 expression a clinical outcome; (D) Kaplan–Meier
analysis of AGO2 expression in ERα ERα− tumor samples with correlation with re urrence free
survival for pooled breast canc les obtained from Breast Cancer Gene-Expression Miner v3.0.
AE: number of events associated with s rvival, death or relapse; HR: hazard ratio.
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Table 1. AGO2 expression is inversely related to breast cancer clinical prognosis in ERα+ tumors but
not ERα− tumors.
# Population and Event Criteria 1 p Value HR 95% CI Good Prognosis RNA Level No. Patients
1 N- ERm AE <0.0001 1.25 1.15–1.36 Low 1799
2 Nm ERm MR <0.0001 1.21 1.12–1.30 Low 2565
3 Nm ERm AE <0.0001 1.16 1.10–1.24 Low 3300
4 N− ER+ AE <0.0001 1.30 1.17–1.45 Low 1388
5 Nm ER+ MR <0.0001 1.26 1.14–1.39 Low 1929
6 N− ER+ MR <0.0001 1.33 1.17–1.52 Low 1146
7 N− ERm MR <0.0001 1.24 1.12–1.37 Low 1492
8 Nm ER+ AE <0.0001 1.18 1.09–1.28 Low 2483
9 N+ ERm MR 0.0549 1.13 1.00–1.29 Low 842
10 N+ ER+ MR 0.1156 1.14 0.97–1.34 – 652
11 N− ER AE 0.1564 1.13 0.95–1.33 – 390
12 Nm ER AE 0.4186 1.05 0.94–1.17 – 774
13 N+ ER AE 0.4618 0.93 0.77–1.13 – 226
14 N+ ER MR 0.5316 0.92 0.72–1.19 – 173
15 Nm ER MR 0.6938 1.03 0.89–1.18 – 601
16 N+ ER+ AE 0.7713 0.98 0.86–1.11 – 815
17 N− ER MR 0.8048 1.02 0.84–1.24 – 330
18 N+ ERm AE 0.8467 1.01 0.91–1.12 – 1058
11 N− ER AE 0.1564 1.13 0.95–1.33 – 390
12 Nm ER AE 0.4186 1.05 0.94–1.17 – 774
13 N+ ER AE 0.4618 0.93 0.77–1.13 – 226
14 N+ ER MR 0.5316 0.92 0.72–1.19 – 173
15 Nm ER MR 0.6938 1.03 0.89–1.18 – 601
16 N+ ER+ AE 0.7713 0.98 0.86–1.11 – 815
17 N− ER MR 0.8048 1.02 0.84–1.24 – 330
18 N+ ERm AE 0.8467 1.01 0.91–1.12 – 1058
1 ER = estrogen receptor status, N = nodal status, and event (AE = any event, MR = metastatic relapse).
HR: hazard ratio; CI: confidence interval.
2.2. Overexpression of AGO2 Represses Estrogen Signaling through Inhibition of ERα in Vitro but Does Not
Diminish E2-Stimulated Tumorigenesis in Vivo
To better understand the relationship between the AGO2 and ERα+ breast cancer phenotype,
the ERα+ MCF-7 breast cancer cell line was stably transfected with a pIRES-AGO2 or pIRES-vector
plasmid. MCF-7-AGO2 cells demonstrated a significant increase in AGO2 expression compared
to MCF-7-vector cells both in mRNA and at the protein level (Figure S1A,B). To investigate the
effects of AGO2 overexpression on estrogen signaling, we examined the expression of ERα and the
ERα-regulated gene PGR in the MCF-7-vector and MCF-7-AGO2 cell lines. Basal ERα and PGR gene
expression was decreased (Figure 2A) and ERα was suppressed at the protein level (Figure 2B) in the
MCF-7-AGO2 cell line compared to MCF-7-vector. Repression of E2-induced stimulation of PGR was
also observed (Figure 2C).
To determine if the changes observed in the MCF-7-AGO2 cell line in vitro translated to a similar
response in vivo, ovariectomized SCID/Beige female mice were inoculated with either MCF-7-vector
or MCF-7-AGO2 cells in the mammary fat pad in the presence of exogenous E2 (0.72 mg pellet, 60-day
release, vs. placebo). E2 stimulated tumorigenesis was not inhibited by AGO2, and demonstrated
significantly greater overall tumor growth kinetics as evaluated with area under the curve analysis
(AUC) (Figure 3A,B) [26]. ERα protein expression was next evaluated in AGO2 tumors compared to
vector. In our in vivo models there was no significant change in ERα protein expression as observed
through immunohistochemistry staining (Figure 3C,D).
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Figure 2. AGO2 expression suppresses ERα function in vitro. (A) MCF‐7‐AGO2 cell line was analyzed 
by quantitative PCR  (qPCR)  for ERα and progesterone receptor  (PGR) expression  levels vs. MCF‐7‐
vector, n = 3 biological replicates; (B) Western blot for ERα protein levels in the MCF‐7‐AGO2 cell line, 
n = 3 biological replicates; (C) qPCR for PGR gene expression levels in MCF‐7‐AGO2 cell line vs. vector 
following 24 h of stimulation with 1 nM E2, n = 4 biological replicates. Significantly different * p < 0.05, 
*** p < 0.001. 
To determine if the changes observed in the MCF‐7‐AGO2 cell line in vitro translated to a similar 
response in vivo, ovariectomized SCID/Beige female mice were inoculated with either MCF‐7‐vector 
or MCF‐7‐AGO2 cells in the mammary fat pad in the presence of exogenous E2 (0.72 mg pellet, 60‐
day release, vs. placebo). E2 stimulated tumorigenesis was not inhibited by AGO2, and demonstrated 
significantly greater overall tumor growth kinetics as evaluated with area under the curve analysis 
(AUC) (Figure 3A,B) [26]. ERα protein expression was next evaluated in AGO2 tumors compared to 
vector. In our in vivo models there was no significant change in ERα protein expression as observed 
through immunohistochemistry staining (Figure 3C,D). 
Figure 2. AGO2 expression suppress α function in vitro. (A) MCF-7-AGO2 cell line was
analyzed by quantitative PCR (qPCR) for ERα and progesterone receptor (PGR) expression levels vs.
MCF-7-vector, n = 3 bi logical replicates; (B) West rn blot for ERα protein lev ls in the MCF-7-AGO2
cell line, n = 3 biological replicates; (C) qPCR for PGR gene expression levels in MCF-7-AGO2 cell line
vs. vector following 24 h of stimulation with 1 nM E2, n = 4 biological replicates. Significantly different
* p < 0.05, *** p < 0.001.
1 
 
 
Figure 3. AGO2 enhances estrogen stimulated tumorigenesis in vivo. (A,B) Immunocompromised
mice were inoculated with either 5 million MCF-7-vector or MCF-7-AGO2 cell lines in the presence of
60-day release estrogen pellet. (A) Results represent average tumor volume; (B) Results represent area
under the curve (AUC). For all experiments error bars represent standard error of the mean (SEM),
n = 10 for vector and n = 9 for AGO2 biological replicates. Significantly different *** p <0.001 (C) Tumors
derived from MCF-7-AGO2 and MCF-7-vector inoculated mice were stained for ERα expression with
immunohistochemistry, images obtained at 10×magnification. (D) Graphical representation of ERα
staining from tumor samples, error bars represent SEM.
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2.3. AGO2 Expression Selectively Increases ERα-36 Isoform Expression
AGO2 increased E2-stimulated tumorigenesis in vivo and this may indicate that AGO2 mediates
components of the estrogen signaling pathway. To identify possible mechanisms for the enhanced E2
response observed in vivo, we analyzed TCGA ERα positive breast cancer samples for a correlation
of expression between AGO2 and ERα transcript gene expression. Of all evaluated transcripts,
three ERα transcripts demonstrated a significant correlation with AGO2 expression. The most
significantly correlated transcript with AGO2 gene expression was truncated three exon long ERα
transcript (Figure 4A). Next, we examined expression of the truncated ERα splice variant ERα-36
in the MCF-7-AGO2 cell line. Quantitative polymerase chain reaction (qPCR) demonstrated that
ERα-36 expression levels were significantly increased in the MCF-7-AGO2 cell line compared to vector
control (Figure 4B). Western blot analysis for ERα-36 protein expression demonstrated increased
ERα-36 expression in the MCF-7-AGO2 cell line versus vector (Figure 4C). ERα-36 is associated with
tamoxifen resistance in breast cancer cells that exhibit resistance to endocrine therapies [10]. To further
determine if a correlation exists between AGO2, ERα-36, and endocrine resistance, we next evaluated
expression of AGO2 in the tamoxifen and ICI 182,780 resistant cell lines, MCF-7-TAMR and MCF-7-F
respectively. Surprisingly, qPCR results demonstrated a loss of AGO2 gene expression in both the
MCF-7-TAMR and MCF-7-F cell lines (Figure 4D). Evaluation of ERα and ERα-36 gene expression in
these endocrine resistant cell lines demonstrated that ERα is repressed in both cell lines (in accordance
with previously published data) and ERα-36 is deregulated in endocrine resistant cell lines [27].
ERα-36 demonstrated elevated expression in the MCF-7-TAMR cell line while it was repressed in the
MCF-7-F cell line (Figure 4E). These data suggest there is not a universal correlation between AGO2
and endocrine resistance.
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Figure 4. AGO2 expression selectively increases ERα‐36 isoform expression. (A) qPCR for ERα‐36 gene 
expression in the MCF‐7‐AGO2 cell line compared to vector and (B) Western blot for ERα‐36 protein 
expression in the MCF‐7‐AGO2 cell line versus vector. Normalization was to Rho GDIα; (C) qPCR for 
AGO2 expression  in MCF‐7‐parental, 4‐OH tamoxifen resistant and ICI 182,780 resistant cell  lines, 
MCF‐7, MCF‐7‐TAMR and MCF‐7‐F, respectively (D) qPCR for ERα and ERα‐36 gene expression in 
MCF‐7‐parental, 4‐OH tamoxifen resistant and ICI 182,780 resistant cell lines, MCF‐7, MCF‐7‐TAMR 
and MCF‐7‐F,  respectively.  Error  bars  represent  SEM.  Significantly  different  *  p  <0.05. All  n  =  3 
biological replicates. 
miRNAs  are master  regulators  of many  signaling  pathways  including  those  involved  in  ERα 
signaling. Since AGO2 is a known mediator of miRNA biogenesis, a miRNA gene array was performed 
to determine miRNA expression levels in the MCF7‐AGO2 cell line compared to vector. As expected, 
several miRNAs were altered in the MCF‐7‐AGO2 cell line (Table S1). Interestingly, many of these 
miRNAs are known to either directly regulate ERα or enhance endocrine resistance [28]. These data 
suggest a possible mechanism  for miRNA  in  the  induction of an E2 response observed  following 
overexpression of AGO2, however further investigations are warranted. 
3. Discussion 
Patients with  luminal B and ER+/PGR−  tumors have a poor response  to endocrine  therapies, 
including  tamoxifen. The underlying mechanism appears  to be deregulation  in estrogen  receptor 
signaling pathways [2,29], due to crosstalk of growth factor signaling pathways. PI3K/AKT/mTOR and 
the epidermal growth factor receptor (EGFR) crosstalk with ERα signaling to enhance pro‐proliferative 
ERα regulated gene expression and suppress PGR gene expression [2]. AGO2, a key component of 
miRNA induced gene silencing, is regulated by the EGFR/MAPK signaling cascade and high AGO2 
expression levels in ERα− breast cancers have been reported [14]. Here, we demonstrate for the first 
time, high AGO2 expression levels in a subset of ERα+ breast tumors (luminal B and ERα+/PGR−), 
Figure 4. AGO2 expression selectively increases ERα-36 isoform expression. (A) qPCR for ERα-36 gene
expression in the MCF-7-AGO2 cell line compared to vector and (B) Western blot for ERα-36 protein
expression in the MCF-7-AGO2 cell line versus vector. Normalization was to Rho GDIα; (C) qPCR
for AGO2 expression in MCF-7-parental, 4-OH tamoxifen resistant and ICI 182,780 resistant cell lines,
MCF-7, MCF-7-TAMR and MCF-7-F, respectively (D) qPCR for ERα and ERα-36 gene expression in
MCF-7-parental, 4-OH ta oxifen resistant and ICI 182,780 resistant cell lines, MCF-7, MCF-7-TAMR
and MCF-7-F, respectively. rr r bars represent SEM. Significantly different * p <0.05. All n = 3
biological replicates.
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miRNAs are master regulators of many signaling pathways including those involved in ERα
signaling. Since AGO2 is a known mediator of miRNA biogenesis, a miRNA gene array was performed
to determine miRNA expression levels in the MCF7-AGO2 cell line compared to vector. As expected,
several miRNAs were altered in the MCF-7-AGO2 cell line (Table S1). Interestingly, many of these
miRNAs are known to either directly regulate ERα or enhance endocrine resistance [28]. These data
suggest a possible mechanism for miRNA in the induction of an E2 response observed following
overexpression of AGO2, however further investigations are warranted.
3. Discussion
Patients with luminal B and ER+/PGR− tumors have a poor response to endocrine therapies,
including tamoxifen. The underlying mechanism appears to be deregulation in estrogen receptor
signaling pathways [2,29], due to crosstalk of growth factor signaling pathways. PI3K/AKT/mTOR
and the epidermal growth factor receptor (EGFR) crosstalk with ERα signaling to enhance
pro-proliferative ERα regulated gene expression and suppress PGR gene expression [2]. AGO2,
a key component of miRNA induced gene silencing, is regulated by the EGFR/MAPK signaling
cascade and high AGO2 expression levels in ERα− breast cancers have been reported [14]. Here, we
demonstrate for the first time, high AGO2 expression levels in a subset of ERα+ breast tumors (luminal
B and ERα+/PGR−), similar to AGO2 expression observed in ERα− tumors. Furthermore, we show
that high AGO2 gene expression levels in ERα+ tumors correlate with a poor prognosis, in contrast
to a lack of correlation between AGO2 expression levels and clinical outcome for ERα− tumor types.
Among ERα+ tumor types, loss of PGR expression correlates with aberrant estrogen signaling, and
we show that AGO2 expression in an ERα+ breast cancer cell line can repress classical ERα signaling
(loss of ERα expression and loss of E2 stimulation of PGR; Figure 2). Additionally, we show that
despite the loss of classical estrogen signaling in vitro, estrogen-stimulated tumorigenesis is increased
and there is no significant change. As a mechanism for altered ERα signaling, we next evaluated
ERα-36 expression levels in the MCF-7 AGO2 cell line. AGO2 overexpression enhanced the expression
of ERα-36 both at the gene and protein level. ERα-36 is involved in rapid estrogen signaling and
its expression correlates with endocrine resistance. Surprisingly, MCF-7 generated with acquired
endocrine resistance to tamoxifen (MCF-7-TAMR) and ICI (MCF-7-F) did not have enhanced ERα-36
gene expression. This study suggests that there may be a greater need in evaluating the alterations in
miRNA biogenesis and associated genes in breast cancers demonstrating endocrine resistance.
4. Materials and Methods
4.1. Cells and Reagents
MCF-7 human breast cancer cell line was purchased from American Type Culture Collection
(Manassas, VA, USA). MCF-7 and MCF-7-AGO2 validation of authenticity is provided as supplemental
(Text S1 and S2 respectively). The MCF-7-TAMR and MCF-7-F cell lines were generated as previously
described [27]. Cells lines were cultured as previously described [30]. Liquid nitrogen stocks were
made upon receipt and maintained until the start of study. ERE-luciferase and/or qPCR for ERα and
PGR were used to confirm MCF-7 sustained estrogen responsiveness. Morphology and doubling times
were also recorded regularly to ensure maintenance of phenotype for all cell lines. Cells were used for
no more than 6 months in culture. Cells were maintained in 10% fetal bovine serum (FBS) Dulbecco’s
modified Eagle’s medium (DMEM) as previously described [31]. MCF-7 parental cells were thawed at
passage 65 and were not used past passage 80. The MCF-7-AGO2 cell line was used at passage 7 to
passage 25. 17β-Estradiol (E2) was purchased from Sigma-Aldrich (St. Louis, MO, USA).
4.2. Transfection of MCF-7 Cell Line
Parental MCF-7 cell line (passage 65) was stably transfected with pIRES-vector or pIRES-AGO2
plasmid (Addgene plasmid 10821 and 45567, Cambridge, MA, USA) with Lipofectamine 2000
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per manufacturer’s protocol (Invitrogen, Grand Isles, NY, USA). Parental MCF-7 cells were grown
in 100 mm dishes. The plasmid (5 µg) was added to 100 µL serum free opti-MEM followed by 15 µL
Lipofectamine. After 30 min incubation, opti-MEM containing the plasmid was added. The following
day, pIRES-transfected cells were treated with 200 ng/mL neomycin. Cells were grown in 10% DMEM
and treated with 200 ng/mL neomycin every two days for 2 weeks. Colonies were pooled and
verification of AGO2 overexpression was confirmed using qPCR. Stable pools of transfected cells were
maintained in 10% DMEM as described above and were not used beyond passage 25.
4.3. RNA Extraction and Quantitative Real Time RT-PCR
MCF-7-pIRES-vector and MCF-7-AGO2 cells were harvested for total RNA extraction using Qiagen
RNeasy ( Valencia, CA, USA). Quantity and quality of the RNA were determined by absorbance at 260
and 280 nm using the NanoDrop ND-1000. Total RNA (1 µg) was reverse-transcribed using the iScript
kit (Bio-Rad Laboratories, Hercules, CA, USA) and qPCR was performed using SYBR-green and 300 ng
cDNA (Bio-Rad Laboratories). β-Actin, PGR, ERα, and ERα-36 genes were amplified (n = 3) using the
following primers: ERα forward 5′-GGCATGGTGGAGATCTTCGA-3′, ERα reverse 5′-CCTCTCCC
TGCAGATTCATCA-3′, ERα-36 forward 5′-CAAGTGGTTTCCTCGTGTCTAAAGC-3′, ERα-36 reverse
5′-TGTTGAGTGTTGGTTCCAGG–3′, PGR forward 5′-TACCCGCCCTATCTCAACTACC-3′, PGR
reverse 5′-TGCTTCATCCCCACAGATTAAACA-3′, β-actin forward 5′-TGAGCGCGGCTACAG
CTT-3′, β-actin reverse 5′-CCTTAATGTCACACACGATT-3′. For E2 stimulation experiments, cells
were grown in 5% DMEM for 48 h prior to 18 h of treatment with 1 nM E2. Data were analyzed by
comparing relative target gene expression to β-actin. Relative gene expression was analyzed using
2−∆∆Ct method. qPCR for miRNA was as follows: total RNA was extracted using the Qiagen miRNeasy
kit as per the manufacturer’s protocol, small RNA fraction was not selected, 1.5 µg of total RNA was
reverse transcribed using the Qiagen miscript II kit and qPCR was performed using miscript SYBR
green and primers for U6 purchased from Qiagen. Normalization was to U6.
4.4. Western Blot
MCF-7-vector and MCF-7-AGO2 cells were grown in 10% FBS DMEM. Cells were washed with
phosphate-buffered saline (PBS) and lysed with M-Per lysis buffer supplemented with 1% protease
inhibitor and 1% phosphatase inhibitors (I/II) (Invitrogen). Supernatant containing protein extracts
was obtained through centrifugation at 12,000 rpm (5415, Eppendorf, Westbury, NY, USA) for 10 min
at 4 ◦C. Protein extracted per sample was determined by absorbance at 260 and 280 nm. Proteins were
heat denatured and loaded on Bis-Tris-nuPAGE gel (Invitrogen). Protein transfer to nitrocellulose
through iBlot and iBlot transfer stacks was per the manufacturer’s protocol (Invitrogen). Nonspecific
binding was blocked by incubation in 3% milk (in 1% Tris buffered saline-Tween (TBS-T)) for 1 h.
Overnight incubation of membrane with primary antibody for AGO2 diluted 1:1000 (Cell Signaling
Technology, Beverly, MA, USA) and ERα (Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted
1:250, and ERα-36 diluted 1:500 at 4 ◦C followed by 3 × 15 min washes in 1% TBS-T. Membranes
were incubated for 1 h in secondary antibody 1:10,000 dilution (LiCor Bioscience, Lincoln, NE, USA)
followed by 3 × 10 min washes in 1% TBS-T. Band density was determined by LiCor gel imager.
Normalization was to Rho GDI-α (Santa Cruz Biotechnology).
4.5. Animal Studies
Ovariectomized SCID/Beige female mice (4–6 weeks old, Charles River Laboratories; Wilmington,
MA, USA) were allowed a 2-week period of adaptation in a sterile and pathogen-free environment
with food and water ad libitum. Cells were harvested in the exponential growth phase using
a PBS/ethylenediaminetetraacetic acid (EDTA) solution and washed. Viable cells (5 × 106) in 50 µL
of sterile PBS suspension were mixed with 100 µL Reduced Growth Factor Matrigel (BD Biosciences,
Bedford, MA, USA). Injections were administered into the mammary fat pad using 271/2 gauge sterile
syringes. Animals were divided into treatment groups of five mice each: MCF-7 control vector, MCF-7
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control vector plus E2, MCF-7 cells transduced to overexpress AGO2, MCF-7 cells transduced to
overexpress AGO2 plus E2. Placebo or E2 pellets (0.72 mg of estradiol-17β, 60-day release; Innovative
Research of America; Sarasota, FL, USA) were implanted subcutaneously in the lateral area of the neck
using a precision trochar (10 gauge). All procedures in animals were carried out under anesthesia
using a mix of isoflurane and oxygen. Tumor size was measured every 2–3 days using digital calipers.
The volume of the tumor was calculated using the formula: 4/3pi LS2 (L = larger radius; S = shorter
radius). Animals were euthanized by cervical dislocation after exposure to CO2. Tumors were
removed and frozen in liquid nitrogen or fixed in 10% formalin for further analysis. All procedures
involving these animals were conducted in compliance with State and Federal laws, standards of the
U.S. Department of Health and Human Services, and guidelines established by Tulane University
Animal Care and Use Committee. The facilities and laboratory animals program of Tulane University
are accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care.
(Protocol #: 4299R Approval Date: 3/8/2016)
4.6. Immunohistochemistry (IHC)
IHC was performed on 5 µm thickness sections made from paraffin-embedded tumor samples
that were fixed with formalin 10% neutral buffered as described previously [32]. Briefly, slides with
tumor sections were deparaffinized in xylene, dehydrated in ethyl alcohol, rinsed in water and antigen
retrieval was done with Diva declocker for 30 min in a steamer and then incubated with 3% hydrogen
peroxide for 5 min for quenching endogenous peroxides. The slides were rinsed with deionized
water and PBS and then were blocked by incubation in 10% normal goat serum for 30 min. After
blocking, the sections were incubated overnight with anti-ERα rabbit monoclonal primary antibody.
The source of the primary antibody and the dilutions used for IHC are as follows: ERα (1:100; SP1
Thermo Scientific, Waltham, MA, USA). After overnight incubation with primary antibody, slides
were washed with PBS followed by 30 min incubation with biotinylated secondary antibody (Vector
Labs, Burlingame, CA, USA), rinsed in PBS and incubated with ABC reagent (Vector labs) for 30 min.
Finally, 3,3-diaminobenzidine (DAB) was added to the sections and color was allowed to develop for
5 min and counterstained with hematoxylin for 30 s. Internal negative control samples incubated with
either non-specific rabbit IgG, or 10% goat serum instead of the primary antibody showed no specific
staining. Slides were dehydrated and mounted using two drops of Permount.
4.7. MicroRNA PCR Array
MCF-7 cells were plated at a density of 1 million cells in 25 cm2 flasks in normal culture media
(10% DMEM) and allowed to adhere overnight at 37 ◦C. Cells were harvested in PBS, collected by
centrifugation, and total RNA extracted using the miRNeasy kit (Qiagen) according to manufacturer’s
protocol. Quantity and quality of RNA were determined by absorbance (260, 280 nm). SABiosciences
Breast Cancer miRNA PCR array was used to detect changes in miRNA as per the manufacturer’s
protocol and SABiosciences SYBR green (Qiagen).
4.8. Data Sources
TCGA research network breast cancer gene expression data (RNA-seq deep sequencing data)
were viewed through the University of California, Santa Cruz (UCSC) Cancer Genomics Browser.
The breast invasive carcinoma TCGA data set (total of n = 1032 tumor samples) was used and analyzed
for gene expression aligned through the Illumina HiSeq system (Illumina, San Diego, CA, USA). Gene
signatures were based on receptor status (ERα, PGR, and HER2) and molecular subtype (Luminal A,
Luminal B, HER2-enriched, and basal-like). The linear relationships between AGO2 and ERα isoform
RNA expression levels were measured in TCGA data sets for breast and invasive cancer. Pearson
correlation coefficients and corresponding p values were calculated for each isoform with coefficients
and −log10 transformed p values plotted on the X and Y axis, respectively.
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Targeted analysis of prognostic gene expression for AGO2, amongst a cohort of breast tumor
samples, was performed using the Breast Cancer Gene-Expression Miner v3.0. Table 1 designates ERα
status, nodal status, and patient number. Kaplan–Meier analysis was performed from the “pool” of
cohorts, meaning all data sets were merged from all studies and converted to a common scale with
normalization. The prognostic impact of AGO2 was evaluated through the univariate Cox proportional
hazard model obtained through pooled data [24,25].
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Abbreviations
The following abbreviations are used in this manuscript:
AF activation function
AGO2 argonaute 2
EGFR epidermal growth factor receptor
ERα estrogen receptor
HER2/neu V-Erb-B2 Erythroblastic Leukemia Viral Oncogene Homolog 2
MAPK mitogen activated protein kinase
mTOR mammalian target of rapamycin
miRNAs microRNAs
PGR progesterone receptor
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